Ipamorelin Accelerates Neurorecovery in Moderate TBI: 3-Year Male Cohort Study
Reading Time: 2 minutes Introduction Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality among American males, particularly those aged 18-44, who account for over 60% of the 2.8 million annual TBI cases reported by the CDC. Moderate to severe TBI often results in protracted neuroinflammation, axonal degeneration, and impaired neurogenesis, leading to persistent cognitive deficits, motor dysfunction, and neuropsychiatric sequelae. Ipamorelin, a selective growth hormone secretagogue (GHS) and ghrelin mimetic, has emerged as a promising adjunctive therapy by stimulating pulsatile growth hormone (GH) release via the GH/IGF-1 axis without the cortisol-elevating side effects of non-peptide GHS analogs. This article synthesizes...














